Evommune shares are trading lower after the company announced top-line results from its phase 2b trial evaluating the efficacy and safety of EVO756 did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven...

Evommune, Inc.

Evommune, Inc.

EVMN

0.00
Evommune shares are trading lower after the company announced top-line results from its phase 2b trial evaluating the efficacy and safety of EVO756 did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days at 12 weeks at any dose.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.